BG Medicine, Inc. is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. The Company’s BGM Galectin-3 Test is its first United States Food and Drug Administration, or FDA, cleared and CE Marked diagnostic product, available as a blood test in the United States and the European Union. The Company’s BGM Galectin-3 Test was included in the 2013 American College of Cardiology Foundation and the American Heart Association (ACCF/AHA) Guideline for the Management of Heart Failure. The Company markets and sells BGM Galectin-3 Test kits to clinical laboratories, hospitals, and health care providers. BG Medicine N.V. is the Company’s subsidiary.